- Home
- NBIX vs HST Comparison
NBIX vs HST Comparison
Compare NBIX & HST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | HST |
|---|---|---|
| Founded | 1992 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 13.3B |
| IPO Year | 1996 | 1998 |
Fundamental Metrics
Financial Performance| Metric | NBIX | HST |
|---|---|---|
| Price | $130.43 | $20.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 13 |
| Target Price | ★ $175.95 | $18.50 |
| AVG Volume (30 Days) | 1.2M | ★ 7.7M |
| Earning Date | 05-11-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 4.69% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | 0.91 |
| Revenue | $161,626,000.00 | ★ $5,387,000,000.00 |
| Revenue This Year | $22.57 | $6.69 |
| Revenue Next Year | $9.56 | $1.43 |
| P/E Ratio | $27.47 | ★ $22.36 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $84.23 | $12.27 |
| 52 Week High | $160.18 | $20.35 |
Technical Indicators
Market Signals| Indicator | NBIX | HST |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 62.95 |
| Support Level | $122.14 | $19.27 |
| Resistance Level | $129.94 | $20.33 |
| Average True Range (ATR) | 4.39 | 0.51 |
| MACD | -0.72 | 0.07 |
| Stochastic Oscillator | 39.90 | 60.66 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.